Press Release

Chengdu, China, July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development. Through the collaboration, HitGen and MSD scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for MSD’s drug discovery efforts. In addition, HitGen will interrogate their own DELs, consisting of hundreds of billions of compounds, against a selected number of MSD’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to MSD for further research and development. MSD will support the research at HitGen.

Chengdu, China, July 27th, 2018, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Sanofi to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening, to discover novel leads which will be licensed exclusively to Sanofi. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments. Financial details were not disclosed.

Birmingham, UK, July 18, 2018 Aston University, with over one hundred year history, welcomed their important annual day of graduation ceremony which took place at Birmingham Town Hall. Dr. Jin Li, Founder, Chairman & Chief Executive Officer of HitGen Ltd, has made excellent contribution to the area of innovative drug discovery. To recognize the outstanding achievements, Dr. Jin Li, the first entrepreneur from Chinese biotech companies, is awarded the Honorary Doctor of Science (DSc) degree by Aston University.

Watertown, Mass. and CHENGDU, China– May 31, 2018– FORMA Therapeutics and HitGen Ltd. today announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded libraries (DELs). Through this collaborative alliance, scientists from both organizations will contribute innovative library design and screening approaches to identify novel leads against a selected number of FORMA’s therapeutic targets. FORMA will fund the discovery research at HitGen and maintain a world-wide exclusive license for further research and development of any compounds discovered through the collaboration.

28 May 2018, Chengdu, HitGen announces the completion of RMB 250 Million Series B fund raising. This round of fund raising was led by CDH, a leading VC and PE firm in China, and Leadyond capital. According to the company, the proceeds from this round of fund raising will be used to expand and enhance its core drug discovery technology platform, DNA-encoded library design, synthesis and screening, as well as to accelerate the research and development of its therapeutic programs.

Chengdu, China, May 7, 2018– HitGen Ltd. announced that its novel small molecule Class I/IIb HDAC inhibitor HG146 (Category 1 of new chemical drug) received approval by Chinese Food and Drug Administration (CFDA) to begin the clinical trialsforMultiple Myeloma.

Chengdu, China, Apr 20, 2018, Simcere Pharmaceutical Group (Simcere) and HitGen Ltd (HitGen) announced today that they have entered into a license agreement on innovative drug discovery.

Ludwigshafen, Germany, and Chengdu, China, March 13, 2018 –BASFand HitGen Ltd. have entered into a research collaboration to identify novel, small molecule leads for targets of agrochemical interest to BASF.

Chengdu, China，February 6th, 2018 NetVation DL Medicine (“DL Medicine”), a privately held biotechnology company based in Chengdu, China, and focused on the discovery and development of novel drug candidates, announced today that it has entered into a two-year research collaboration with Pfizer Inc (NYSE: PFE). Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas. As part of the collaboration, Pfizer has taken a financial stake in DL Medicine.

Chengdu, China，November 23rd 2017, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest to Boehringer Ingelheim. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Boehringer Ingelheim. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Boehringer Ingelheim. Specific financial details were not disclosed.